贵州三力 (603439)

Guizhou Sanli Pharmaceutical Co., Ltd.

ASH

Tags

SSE 580 IndexSpecialized-Sophisticated-Distinctive-Innovative EnterprisesTraditional Chinese MedicineCSI Share Buyback IndexInnovative DrugsPharmaceutical ManufacturingPharmaceuticals and HealthcareInfant and Child ConceptNew RetailSmart Healthcare

K-Line Chart

No K-line data

Stock Details

1. Key Indicators

  • Total Shares(W): 40980.22
  • Circulating A-Shares(W): 40384.02
  • Earnings Per Share(RMB): 0.20
  • Net Assets Per Share(RMB): 3.61
  • Operating Revenue(W RMB): 103849.84
  • Total Profit(W RMB): 9265.34
  • **Net Profit Attributable to Parent(W RMB) **: 8078.70
  • Net Profit Growth Rate(%): -58.39
  • Weighted Return on Equity(%): 5.37
  • Operating Cash Flow Per Share(RMB): 0.12
  • Undistributed Profit Per Share(RMB): 2.15
  • Capital Reserve Per Share(RMB): 0.39

2. Main Business

The main business covers:

  • Research, development, production, and sales of pharmaceuticals.

3. Company Basic Information

  • Company Name: Guizhou Sanli Pharmaceutical Co., Ltd.
  • Listing Date: 2020-04-28
  • Industry: Pharmaceutical Manufacturing
  • Address: Xiayun Industrial Park, Pingba District, Anshun City, Guizhou Province
  • Website: https://www.gz-sanli.com
  • Company Profile: The company was established through the overall change of Sanli Co., Ltd. into a joint stock company. On January 5, 2015, Sanli Co., Ltd. passed a resolution at the shareholders' meeting to convert the audited net assets of 108.9159 million RMB as of December 31, 2014, into 50.15 million shares, thus transforming the company into a joint stock company. On January 30, 2015, the company completed its industrial and commercial registration with the Guizhou Provincial Administration for Industry and Commerce and obtained a business license with the registration number 520000000029334.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Hainan Yuexin Pharmaceutical Investment Partnership (General Partnership) Corporate Entity 2019.01 5.00
2 Shanghai Guosheng Capital Management Co., Ltd. - Shanghai Guosheng Haitong Private Equity Investment Fund Partnership (Limited Partnership) for High-Quality Development of Private Enterprises Asset Management Plan 777.57 1.93
3 Guizhou Sanli Pharmaceutical Co., Ltd. Special Securities Account for Repurchase Corporate Entity 419.02 1.04

5. Concept Sectors

  • New Retail
  • Infant and Child Concept
  • Smart Healthcare
  • Innovative Drugs
  • Specialized, Refined, Unique, and New (SRUN) Enterprises
  • CSI Repurchase Index
  • SSE 580 Index

Remarks

  • Data update date: 2025-10-27
  • Data source: Public market information